 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | New P1/2 trial, Metastases: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy (clinicaltrials.gov) - Sep 21, 2022
P1/2, N=73, Recruiting, Sponsor: Cellbion Co., Ltd.